Friday 6 November 2026
Export NTRA’s income statement to Excel — free account
Natera, Inc.
NTRA Healthcare Diagnostics & Research
Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024.
- Revenue
- +34.1%
- EPS
- +34.4%
- Free cash flow
- −85.8%
- Total debt
- −0.06%
Quarter to September 2026, against a year earlier
313.12
50.64
−13.92%
Follow NTRA
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
20.47 | 14.37 | 11.32 | 13.58 | |
P/FCF ratio |
1,134.89 | 461.93 | 270.78 | 287.05 | |
P/Operating CF |
1,355.41 | 709.82 | 704.46 | 423.90 | |
P/B ratio |
31.85 | 21.35 | 15.95 | 18.29 | |
Price to Tangible BV |
43.52 | 29.46 | 22.36 | 26.15 | |
EV/Sales |
20.22 | 14.10 | 11.03 | 13.27 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
276.43 | 167.23 | 130.69 | 142.18 | |
EV/FCF |
1,121.08 | 453.32 | 263.88 | 280.55 | |
Quick Ratio |
0.77 | 2.74 | 2.70 | 3.11 | |
Current Ratio |
2.81 | 3.00 | 2.96 | 3.39 | |
Net Debt/EBITDA |
0.00 | 18.52 | 13.75 | 114.60 | |
Debt/Assets |
2.92% | 3.02% | 3.07% | 3.35% | |
Debt/Equity |
0.04 | 0.04 | 0.05 | 0.05 | |
Asset Turnover |
1.27 | 1.23 | 1.15 | 1.14 | |
Operating CF/Net income |
(0.73) | (0.82) | (0.47) | 1.56 | |
Capex/Depreciation |
0.00 | (2.99) | (1.09) | (2.56) | |
Interest Coverage |
— | (85.16) | (104.84) | (23.02) | |
Research and Development Expense of Revenue |
30.53% | 30.30% | 30.25% | 26.33% | |
Selling, General and Administrative Expense of Revenue |
42.02% | 43.47% | 47.07% | 43.77% | |
Intangible Assets out of Total Assets |
0.00 | 0.19 | 0.19 | 0.21 | |
Share Based Compensation of Revenue |
13.36% | 13.70% | 13.65% | 13.91% | |
Graham Net Nets |
0.01 | 0.02 | 0.03 | 0.03 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(0.28%) | (0.50%) | (0.82%) | (0.67%) | |
Free Cash Flow Yield |
0.09% | 0.22% | 0.37% | 0.35% | |
Revenue per Share |
5.51 | 5.25 | 4.92 | 4.87 | |
Operating CF per Share |
0.30 | 0.38 | 0.28 | 0.54 | |
Capex per Share |
(0.27) | (0.44) | (0.16) | (0.26) | |
Free Cash Flow per Share |
0.04 | (0.06) | 0.13 | 0.28 | |
Cash per Share |
0.00 | 7.62 | 7.69 | 7.87 | |
Shareholders Equity per Share |
12.98 | 12.71 | 12.54 | 12.52 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
12.98 | 12.71 | 12.54 | 12.52 | |
Free Cash Flow |
5.25 | (8.64) | 18.03 | 37.82 | |
Working Capital |
1,109.72 | 1,105.75 | 1,093.56 | 1,055.71 | |
Capital Expenditures |
(38.68) | (63.43) | (22.14) | (36.07) | |
Net Current Asset Value |
843.76 | 822.95 | 811.43 | 811.01 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.08 | 0.03 | 0.05 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
378.87 | 365.60 | 367.91 | 305.35 | |
Average Payables |
83.34 | 56.02 | 50.82 | 34.04 | |
Average Inventory |
78.17 | 67.31 | 60.54 | 56.59 | |
Average Assets |
2,284.95 | 2,207.28 | 2,173.38 | 2,029.54 | |
Average Common Equity |
1,560.87 | 1,533.84 | 1,506.85 | 1,453.92 |
Columns are period end dates · fundamentals updated 5 Nov 2026